XTLB XTL Biopharmaceuticals Ltd

VALLEY COTTAGE, N.Y., Jan. 7 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the 26th Annual JPMorgan Healthcare Conference. Mr. Bentsur will present an overview of the Company including a discussion of Bicifadine, the Company's late-stage clinical compound for the treatment of diabetic neuropathic pain. Mr. Bentsur's presentation will take place on Thursday, January 10, 2008 at 1:00 pm PST at the Westin St. Francis in San Francisco. A live webcast of the presentation will be available at: http://www.metameetings.com/webcasts/jpmorgan/healthcare08. An archived version of the webcast will be available following the conclusion of the live presentation. ABOUT XTL BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL is also developing novel pre-clinical HCV small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL Biopharmaceuticals Ltd. CONTACT: Ron Bentsur, Chief Executive Officer, XTL Biopharmaceuticals Ltd., +1-845-267-0707 ext. 225 Web site:

Copyright